Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Bronstein, Gewirtz & Grossman, LLCBronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmBronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Aardvark securities: (1) pursuant to...
- Bronstein, Gewirtz & Grossman, LLCBronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmBronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Unicycive securities between...
- Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Regeneron (REGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/14/2026
- Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026
- THE ROSEN LAW FIRM, P. A.SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitWhy: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead...
- Faruqi & Faruqi LLPSPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]New York, New...
- 最多10亿港元回购H股股份！复星医药，最新公告Companies: Fosun International Limited炒股就看 金麒麟分析师研报 ，权威，专业，及时，全面，助您挖掘潜力主题机会！ 复星医药 拟不超10亿港元回购H股股份，同时作价2.94亿美元出售控股子公司股权。 9月6日晚间，复星医药（600196）披露，基于对集团发展前景的信心及内在价值的认可，经董事会批准，公司拟自2026年8月27日起12个月内回购H股股份，拟回购资金总额不超过10亿港元。 公司将根据H股回购授权及市场情况等确定已回购H股用途，包括但不限于注销或作为库存股份持有。本次回购须视乎市况，且需符合相关上市规则、法律法规及公司章程规定，公司不保证回购的时间、数量或价格，提醒投资者谨慎交易。 复星医药同时公告，印度时间2026年9月4日，控股子公司复星医药新加坡公司通过大宗交易及集中竞价方式出售共计989.7万股Gland Pharma股份（约占截至2026年9月3日Gland Pharma股份总数的6%），交易总对价（扣除交易佣金及税费前）为279.96亿印度卢比
- 复星医药：拟出售Gland Pharma部分股权Companies: Fosun International Limited格隆汇9月6日｜复星医药公告称，控股子公司复星医药新加坡公司通过大宗交易及集中竞价方式出售989.70万股GlandPharma股份，占其总股本6.00%，交易总对价约2.94亿美元。
- 复星医药(600196.SH)控股子公司复星医药新加坡公司出售989.70万股Gland Pharma股份Companies: Fosun International Limited格隆汇9月6日丨复星医药(600196.SH)公告，印度时间2026年9月4日，控股子公司复星医药新加坡公司通过大宗交易及集中竞价方式出售共计989.70万股GlandPharma股份(约占截至2026年9月3日GlandPharma股份总数的6.00%)，交易总对价(扣除交易佣金及税费前)为279.96亿印度卢比(折合约2.94亿美元1),均价(扣除交易佣金及税费前)约为2,828.78印度卢比...
- Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.
- The Rosen Law Firm PACAPR DEADLINE NOTICE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPRWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Robbins Geller Rudman & Dowd LLPSEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitThe law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) common stock between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"), have until September 14, 2026 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026 (S.D.N.Y.), the...